TD Ameritrade Investment Management’s Charles River Laboratories CRL Stock Holding History

TD Ameritrade Investment Management’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-30	Closed	-$7K	–	632
2021 Q3	$7K	Buy	30 +7	+30%	+$2.91K	﹤0.01%	481
2021 Q2	$9K	Sell	23 -7	-23%	-$2.34K	﹤0.01%	472
2021 Q1	$7K	Hold	30	–	–	﹤0.01%	503
2020 Q4	$7K	Hold	30	–	–	﹤0.01%	503
2020 Q3	$7K	Sell	30 -10	-25%	-$2.08K	﹤0.01%	481
2020 Q2	$7K	Sell	40 -41	-51%	-$6.54K	﹤0.01%	466
2020 Q1	$10K	Buy	81 +11	+16%	+$1.65K	﹤0.01%	411
2019 Q4	$11K	Sell	70 -2	-3%	-$277	﹤0.01%	441
2019 Q3	$10K	Buy	72 +1	+1%	+$134	﹤0.01%	426
2019 Q2	$10K	Sell	71 -4	-5%	-$543	﹤0.01%	389
2019 Q1	$11K	Sell	75 -77	-51%	-$10.1K	﹤0.01%	333
2018 Q4	$17K	Hold	152	–	–	﹤0.01%	311
2018 Q3	$20K	Buy	+152	New	+$18.8K	﹤0.01%	281

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

TD Ameritrade Investment Management's CRL Position: Q4 2021 in Review

TD Ameritrade Investment Management sold out of Charles River Laboratories (CRL) in Q4 2021, closing a stake of 30 shares — an estimated $7K sold.

TD Ameritrade Investment Management first reported a position in CRL in Q3 2018 and held it in 13 quarters. The position peaked at $20K in Q3 2018. 707 funds tracked by Wall St. Rank hold CRL as of Q4 2021.

TD Ameritrade Investment Management reported no remaining Charles River Laboratories position as of Q4 2021 after selling out during the quarter.
TD Ameritrade Investment Management sold 30 Charles River Laboratories shares in Q4 2021, an estimated $7K.
TD Ameritrade Investment Management first reported a position in Charles River Laboratories in Q3 2018 and held it in 13 quarters.
TD Ameritrade Investment Management's Charles River Laboratories position peaked at $20K in Q3 2018.
707 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2021.

Based on TD Ameritrade Investment Management's 13F filing for Q4 2021, filed 11 Feb 2022.